Skip to main content
Bei Hu, MD, Oncology, Charlotte, NC

BeiHuMD

Oncology Charlotte, NC

Cutaneous Lymphoma, Hematologic Oncology

Lymphoma Specialist at Levine Cancer Institute/Atrium Health in Charlotte, NC ; Clinical Assistant Professor at UNC-Chapel Hill

Dr. Hu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Hu's full profile

Already have an account?

  • Office

    1021 Morehead Medical Dr
    Ste A
    Charlotte, NC 28204
    Phone+1 980-442-2000

Summary

  • Lymphoma and apheresis attending at Levine Cancer Institute/Atrium Health. Board certified in Hematology, Medical Oncology, and Internal Medicine

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterResidency, Internal Medicine, 2011 - 2014
  • University of California San Francisco School of Medicine
    University of California San Francisco School of MedicineClass of 2011

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2017 - 2025
  • TX State Medical License
    TX State Medical License 2015 - 2017
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Conquer Cancer Merit Award ASCO, Conquer Cancer Foundation, 2016

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • De Novo CD5+ diffuse large B cell lymphoma: clinic characterististics and clinical outcomes in the Rituximab era  
    2. Hu B, Nastoupil LJ, Westin JR, Logavi S, Thakral B, Fayad LE, Hagemeister G, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y, Leukemia and Lymphoma, 9/18/2019
  • Standardizing opioid prescribing practices for cancer-related pain via a novel interactive documentation template at a public hospital  
    3. Nusrat M, Parkes A, Kieser R, Hu B, Farhat D, Rieber A, Ma H, Journal of Oncology Practice, 6/21/2019
  • A tale of two eras: the story of autologous stem cell transplantation with and without thiotepa for primary central nervous system lymphoma  
    Hu B, Biology of Blood and Marrow Transplantation, 5/2019
  • Join now to see all

Press Mentions

  • Downregulation of SENP1 Suppresses LPS-Induced Macrophage Inflammation by Elevating Sp3 SUMOylation and Disturbing Sp3-NF-κB Interaction
    Downregulation of SENP1 Suppresses LPS-Induced Macrophage Inflammation by Elevating Sp3 SUMOylation and Disturbing Sp3-NF-κB InteractionNovember 15th, 2020
  • High Use of Oncology Nurse Navigators Showed Similar Clinical Outcomes for White, Nonwhite Patients with DLBCL
    High Use of Oncology Nurse Navigators Showed Similar Clinical Outcomes for White, Nonwhite Patients with DLBCLDecember 12th, 2019

Professional Memberships